June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Bunazosin inhibited axial elongation with an increase of the choroidal blood perfusion in a murine model of myopia
Heonuk Jeong; Toshihide Kurihara; Xiaoyan Jiang; Kazuno Negishi; Kazuo Tsubota
Author Affiliations & Notes
  • Heonuk Jeong
    Department of Ophthalmology, Keio Gijuku Daigaku Igakubu Daigakuin Igaku Kenkyuka, Shinjuku-ku, Tokyo, Japan
    Laboratory of Photobiology, Keio Gijuku Daigaku Igakubu Daigakuin Igaku Kenkyuka, Shinjuku-ku, Tokyo, Japan
  • Toshihide Kurihara
    Department of Ophthalmology, Keio Gijuku Daigaku Igakubu Daigakuin Igaku Kenkyuka, Shinjuku-ku, Tokyo, Japan
    Laboratory of Photobiology, Keio Gijuku Daigaku Igakubu Daigakuin Igaku Kenkyuka, Shinjuku-ku, Tokyo, Japan
  • Xiaoyan Jiang
    Department of Ophthalmology, Keio Gijuku Daigaku Igakubu Daigakuin Igaku Kenkyuka, Shinjuku-ku, Tokyo, Japan
    Laboratory of Photobiology, Keio Gijuku Daigaku Igakubu Daigakuin Igaku Kenkyuka, Shinjuku-ku, Tokyo, Japan
  • Kazuno Negishi
    Department of Ophthalmology, Keio Gijuku Daigaku Igakubu Daigakuin Igaku Kenkyuka, Shinjuku-ku, Tokyo, Japan
  • Kazuo Tsubota
    Department of Ophthalmology, Keio Gijuku Daigaku Igakubu Daigakuin Igaku Kenkyuka, Shinjuku-ku, Tokyo, Japan
    Tsubota Laboratory, Inc, Japan
  • Footnotes
    Commercial Relationships   Heonuk Jeong Tsubota Laboratory, Inc., Code P (Patent); Toshihide Kurihara Tsubota Laboratory, Inc., Restore Vision Co., Ltd., Code I (Personal Financial Interest), Tsubota Laboratory, Inc., Code P (Patent); Xiaoyan Jiang Tsubota Laboratory, Code P (Patent); Kazuno Negishi SEED Co., Ltd., Code F (Financial Support), Keio University School of Medicine, Code P (Patent); Kazuo Tsubota Tsubota Laboratory, Inc., Code E (Employment), Tsubota Laboratory, Inc., Code F (Financial Support), TissueTech, Inc., Restore Vision Co., Ltd., Tsubota Laboratory, Inc., Cellusion Inc., Code I (Personal Financial Interest), Tsubota Laboratory, Inc., Code P (Patent), Tsubota Laboratory, Inc., Code R (Recipient)
  • Footnotes
    Support  KAKENHI Grant-in-Aid for Young Scientists 20K18357
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 1451 – F0409. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Bunazosin inhibited axial elongation with an increase of the choroidal blood perfusion in a murine model of myopia
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Heonuk Jeong, Toshihide Kurihara, Xiaoyan Jiang, Kazuno Negishi, Kazuo Tsubota; Bunazosin inhibited axial elongation with an increase of the choroidal blood perfusion in a murine model of myopia. Invest. Ophthalmol. Vis. Sci. 2022;63(7):1451 – F0409.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose : The prevalence of myopia is accelerating worldwide possibly because of the decrease in outdoor activity including COVID-19 home confinement. We have reported the effective treatments of suppressing myopia progression, including oral administration of crocetin (Mori K et al. Sci Rep. 2019) and violet light exposure (Jiang X et al. Proc Natl Acad Sci USA. 2021). In this study, we examined the therapeutic effects of bunazosin, known as one of the α1-adrenergic receptor antagonists, in a lens-induced myopia mouse model.

Methods : C57BL/6J mice were induced myopia at 3-week-old by a method established in our research group (Jiang X et al. Sci Rep. 2018). For 3 weeks, mice were equipped with lenses in both eyes, a left for 0 D lens as internal control and a right for -30 D lens as myopia induction. During this period, we administered 0.01% bunazosin hydrochloride solution by intraperitoneal injection (IP group) and eye drop (E group) once a day, and PBS as control. Ocular components including refraction error, axial length, and choroidal thickness before and after myopia induction were measured by an infrared photorefractor and an SD-OCT. The choroidal blood flow was evaluated by an SS-OCT angiography.

Results : In the eye with -30D lens of control group, significant changes in a myopic shift of refraction (p < 0.01), axial elongation (p < 0.05), and choroidal thinning (p < 0.01) compared to 0D lens were observed. In contrast, IP or E groups showed no significant difference between both eyes, suggesting myopia progression was suppressed by bunazosin treatment. The choroidal blood flow of the eye with -30D in E group (58.9±8.9%) was higher than that of the control group -30D (44.0±6.4%)(p < 0.05).

Conclusions : Bunazosin has a preventive effect on myopia progression by suppressing axial elongation and choroidal thinning together with an increase of choroidal blood flow.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Attribution-NonCommercial-NoDerivatives
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept